StockMacro
Company, fund or insider

Help

Menu

Agios Pharmaceuticals

$27.60 -2.6% in 6 monthsMarket cap $1.7B

AGIO on XNAS, Health Care, Agios Pharmaceuticals, Inc., job postings

Measures activity, not value. Not investment advice.

Quarterly revenue jumped 330% to $55.4M but the company lost $372.9M over 12 months.

  • BadFree cash flow of -$336M over the last 12 months, cash going out
  • WatchShares fell 26% in one month; still up 12% over 12 months

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Industry
Pharmaceutical preparations (Health Care)
Employees
540
Website
agios.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $55.4M, net loss $65.0M.
Quarter to 31 Dec 2021: revenue –, net income -$94.6MQuarter to 31 Mar 2022: revenue $832K, net income -$94.8MQuarter to 31 Mar 2022: revenue $832K, net income -$94.8MQuarter to 30 Jun 2022: revenue $5.6M, net income -$91.8MQuarter to 30 Jun 2022: revenue $5.6M, net income -$91.8MQuarter to 30 Sep 2022: revenue $3.5M, net income -$81.7MQuarter to 30 Sep 2022: revenue $3.5M, net income -$81.7MQuarter to 31 Dec 2022: revenue –, net income $36.5MQuarter to 31 Mar 2023: revenue $5.6M, net income -$81.0MQuarter to 31 Mar 2023: revenue $5.6M, net income -$81.0MQuarter to 30 Jun 2023: revenue $6.7M, net income -$83.8MQuarter to 30 Jun 2023: revenue $6.7M, net income -$83.8MQuarter to 30 Sep 2023: revenue $7.4M, net income -$91.3MQuarter to 30 Sep 2023: revenue $7.4M, net income -$91.3MQuarter to 31 Dec 2023: revenue $7.1M, net income -$95.9MQuarter to 31 Dec 2023: revenue $7.1M, net income -$95.9MQuarter to 31 Mar 2024: revenue $8.2M, net income -$81.5MQuarter to 31 Mar 2024: revenue $8.2M, net income -$81.5MQuarter to 30 Jun 2024: revenue $8.6M, net income -$96.1MQuarter to 30 Jun 2024: revenue $8.6M, net income -$96.1MQuarter to 30 Sep 2024: revenue $9.0M, net income $947.9MQuarter to 30 Sep 2024: revenue $9.0M, net income $947.9MQuarter to 31 Dec 2024: revenue $10.7M, net income -$96.5MQuarter to 31 Dec 2024: revenue $10.7M, net income -$96.5MQuarter to 31 Mar 2025: revenue $8.7M, net income -$89.3MQuarter to 31 Mar 2025: revenue $8.7M, net income -$89.3MQuarter to 30 Jun 2025: revenue $12.5M, net income -$112.0MQuarter to 30 Jun 2025: revenue $12.5M, net income -$112.0MQuarter to 30 Sep 2025: revenue $12.9M, net income -$103.4MQuarter to 30 Sep 2025: revenue $12.9M, net income -$103.4MQuarter to 31 Dec 2025: revenue $20.0M, net income -$108.0MQuarter to 31 Dec 2025: revenue $20.0M, net income -$108.0MQuarter to 31 Mar 2026: revenue $20.7M, net income -$99.1MQuarter to 31 Mar 2026: revenue $20.7M, net income -$99.1MQuarter to 30 Jun 2026: revenue $44.7M, net income -$100.7MQuarter to 30 Jun 2026: revenue $44.7M, net income -$100.7MQuarter to 30 Sep 2026: revenue $55.4M, net income -$65.0MQuarter to 30 Sep 2026: revenue $55.4M, net income -$65.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $947.9M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$55.4M-$65.0M
30 Jun 2026$44.7M-$100.7M
31 Mar 2026$20.7M-$99.1M
31 Dec 2025$20.0M-$108.0M
30 Sep 2025$12.9M-$103.4M
30 Jun 2025$12.5M-$112.0M
31 Mar 2025$8.7M-$89.3M
31 Dec 2024$10.7M-$96.5M
30 Sep 2024$9.0M$947.9M
30 Jun 2024$8.6M-$96.1M
31 Mar 2024$8.2M-$81.5M
31 Dec 2023$7.1M-$95.9M
30 Sep 2023$7.4M-$91.3M
30 Jun 2023$6.7M-$83.8M
31 Mar 2023$5.6M-$81.0M
31 Dec 2022–$36.5M
30 Sep 2022$3.5M-$81.7M
30 Jun 2022$5.6M-$91.8M
31 Mar 2022$832K-$94.8M
31 Dec 2021–-$94.6M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $140.8M $44.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +214% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$372.9M -$401.3M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$6.32 -$7.00
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 93.8% 87.2% 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -298% – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -265% -896% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -32.9% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$336.0M -$414.1M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $907.0M $1.3B
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$907.0M (net cash) -$1.3B
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $16.37
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 11.7 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 5.3 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.7 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Agios PharmaceuticalsAGIO (this company) $1.7Bloss11.7+214%-265%
Ultragenyx PharmaceuticalRARE $1.7Bloss2.3+16%-71.7%
Zenas BioPharmaZBIO $1.6Bloss–––
Korsana BiosciencesKRSA $1.7Bloss–––
SchrodingerSDGR $1.7Bloss6.4+4.8%-22.0%
ANI PharmaceuticalsANIP $1.6B13.31.5+26%11.2%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+330%

$55.4M vs $12.9M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-24%

$1.2M vs $1.6M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$371K

bought $0, sold $371K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+3.4%

241 13F filers vs 233

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

67.0M shares held by 13F filers (30 Sep 2026) of 59.8M outstanding (30 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

11%

6.5M shares sold short (30 Oct 2026) of 59.8M outstanding (30 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

5.2

6.5M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.4%

6.9M shares sold short in the report before, 6.5M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

44%

44% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 48%

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

$73K

the 12 months before: $0

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$150K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Revenue $55.4M, 4.3× a year earlier

Price $27.60 on 20 Nov 2026, +12% over 12 months (12-month range $24.43 to $44.01)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $4.9M in the last 12 months (the 12 months before: -$4.1M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 10 published in the last 12 months, +25% on the 12 months before.
Revenue per quarter. Revenue $55.4M in the latest quarter, +330% on a year earlier.
Capital spending per quarter. Capital spending $1.2M in the latest quarter, -24% on a year earlier.
Institutional holders (13F filers). 241 13F filers reported holding it in the latest 13F quarter, +15% on a year earlier.
Federal obligations. Federal obligations: $73K published in the last 12 months (none in the 12 months before).
Lobbying spend. Lobbying spend: $150K published in the last 12 months, +400% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
10 Nov 2026Sharp changeQuarterly revenue change: quarterly revenue change, 55.4M vs usual 12.7M (2026-09-30); 4.3x the same period a year earlier
4 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 44.7M vs usual 11.6M (2026-06-30); 3.6x the same period a year earlier
18 Jun 20268-K and other filingsDirector or officer change
18 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
26 May 2026Lobbying filingnew lobbying registration (GRIDIRON PUBLIC AFFAIRS, LLC)
30 Apr 2026Sharp changeQuarterly revenue change: quarterly revenue change, 20.7M vs usual 9.8M (2026-03-31); 2.4x the same period a year earlier
17 Feb 2026Sharp changeQuarterly revenue change: quarterly revenue change, 20.0M vs usual 8.8M (2025-12-31); 1.9x the same period a year earlier
3 Feb 2026Sharp changeShort interest spike: short interest spike, 7.4M vs usual 4.5M (2026-01-15); 1.4x the same period a year earlier
9 Jan 2026Lobbying filingnew lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.)
4 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 12.9M vs usual 8.7M (2025-09-30); 1.4x the same period a year earlier
5 Aug 2025Sharp changeQuarterly revenue change: quarterly revenue change, 12.5M vs usual 8.4M (2025-06-30); 1.4x the same period a year earlier
22 Jul 2025Sharp changeLobbying on a new issue: lobbying on a new issue: MMM, PHA (2025-06-30)
8 Jul 20258-K and other filingsDirector or officer change
18 Jun 20258-K and other filingsDirector or officer change
18 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
12 Jun 2025Lobbying filingnew lobbying registration (in-house)
13 Feb 20258-K and other filingsDirector or officer change
13 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Jan 2024Sharp changeShort interest spike: short interest spike, 8.0M vs usual 5.9M (2024-01-12); 1.2x the same period a year earlier
16 Jan 2024Lobbying filinglobbying engagement terminated (TIBER CREEK GROUP)
14 Jun 20238-K and other filingsDirector or officer change
25 May 20238-K and other filingsDirector or officer change
19 Apr 20238-K and other filingsDirector or officer change
19 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Dec 20228-K and other filingsDirector or officer change
6 Dec 20228-K and other filingsDirector or officer change
7 Oct 20228-K and other filingsDirector or officer change
19 Sep 20228-K and other filingsDirector or officer change
7 Sep 20228-K and other filingsDirector or officer change
15 Aug 20228-K and other filingsDirector or officer change
12 Jul 20228-K and other filingsDirector or officer change
26 May 20228-K and other filingsDirector or officer change
18 May 20228-K and other filingsDirector or officer change
26 Apr 20228-K and other filingsDirector or officer change
26 Apr 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Nov 2021Sharp changeShort interest spike: short interest spike, 7.6M vs usual 5.5M (2021-11-15); 1.4x the same period a year earlier
Insider net buying (open market)
Month from 1 Feb 2022: -$23K published
Month from 1 Mar 2022: -$3K published
Month from 1 Jan 2023: -$577K published
Month from 1 Feb 2023: -$1.2M published
Month from 1 Mar 2023: -$1.4M published
Month from 1 Apr 2023: -$374K published
Month from 1 Jul 2023: -$817K published
Month from 1 Aug 2023: -$1.2M published
Month from 1 Sep 2023: -$54K published
Month from 1 Jan 2024: -$1.1M published
Month from 1 Feb 2024: -$2.3M published
Month from 1 Mar 2024: -$3.0M published
Month from 1 Apr 2024: -$215K published
Month from 1 Jun 2024: -$652K published
Month from 1 Jul 2024: -$162K published
Month from 1 Aug 2024: -$474K published
Month from 1 Oct 2024: -$125K published
Month from 1 Nov 2024: -$2.3M published
Month from 1 Dec 2024: -$9K published
Month from 1 Jan 2025: -$90K published
Month from 1 Feb 2025: -$78K published
Month from 1 Mar 2025: -$944K published
Month from 1 Apr 2025: -$194K published
Month from 1 Jun 2025: -$971K published
Month from 1 Jul 2025: -$648K published
Month from 1 Aug 2025: -$414K published
Month from 1 Sep 2025: -$315K published
Month from 1 Oct 2025: -$295K published
Month from 1 Nov 2025: -$125K published
Month from 1 Jan 2026: -$902K published
Month from 1 Mar 2026: -$1.3M published
Month from 1 Apr 2026: -$1.2M published
Month from 1 Jul 2026: -$151K published
Month from 1 Aug 2026: -$914K published
Month from 1 Oct 2026: -$371K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 3 published
Quarter from 1 Apr 2022: 2 published
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Oct 2022: 2 published
Quarter from 1 Jan 2023: 3 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 3 published
Quarter from 1 Oct 2023: 3 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Apr 2024: 3 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Oct 2024: 3 published
Quarter from 1 Apr 2025: 3 published
Quarter from 1 Jul 2025: 2 published
Quarter from 1 Oct 2025: 3 published
Quarter from 1 Jan 2026: 2 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 3 published
Quarter from 1 Oct 2026: 4 published
Revenue per quarter
Quarter ended 31 Mar 2021: $0; public on 6 May 2022
Quarter ended 30 Jun 2021: $0; public on 5 Aug 2022
Quarter ended 30 Sep 2021: $0, -100% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Mar 2022: $832K; public on 6 May 2022
Quarter ended 30 Jun 2022: $5.6M; public on 5 Aug 2022
Quarter ended 30 Sep 2022: $3.5M; public on 4 Nov 2022
Quarter ended 31 Mar 2023: $5.6M, +574% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $6.7M, +20% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $7.4M, +110% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $7.1M; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $8.2M, +46% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $8.6M, +28% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $9.0M, +21% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $10.7M, +51% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $8.7M, +6.6% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $12.5M, +45% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $12.9M, +44% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $20.0M, +86% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $20.7M, +138% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $44.7M, +259% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $55.4M, +330% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2022: $2.8M, +177% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $1.9M; public on 5 Aug 2022
Quarter ended 31 Mar 2023: $399K, -86% on a year earlier; public on 5 May 2023
Quarter ended 30 Sep 2023: $369K; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $234K; public on 16 Feb 2024
Quarter ended 31 Mar 2024: $141K, -65% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $158K; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $419K, +14% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $967K, +313% on a year earlier; public on 14 Feb 2025
Quarter ended 31 Mar 2025: $766K, +443% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $875K, +454% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $1.6M, +271% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $1.1M, +16% on a year earlier; public on 13 Feb 2026
Quarter ended 31 Mar 2026: $769K, +0.4% on a year earlier; public on 30 Apr 2026
Quarter ended 30 Jun 2026: $1.2M, +39% on a year earlier; public on 31 Jul 2026
Quarter ended 30 Sep 2026: $1.2M, -24% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 146; public on 14 Feb 2022
31 Mar 2022 report: 149; public on 16 May 2022
30 Jun 2022 report: 145; public on 15 Aug 2022
30 Sep 2022 report: 156; public on 14 Nov 2022
31 Dec 2022 report: 149; public on 14 Feb 2023
31 Mar 2023 report: 155; public on 15 May 2023
30 Jun 2023 report: 144; public on 14 Aug 2023
30 Sep 2023 report: 136; public on 14 Nov 2023
31 Dec 2023 report: 160; public on 14 Feb 2024
31 Mar 2024 report: 177; public on 15 May 2024
30 Jun 2024 report: 195; public on 14 Aug 2024
30 Sep 2024 report: 202; public on 14 Nov 2024
31 Dec 2024 report: 220; public on 14 Feb 2025
31 Mar 2025 report: 209; public on 15 May 2025
30 Jun 2025 report: 207; public on 14 Aug 2025
30 Sep 2025 report: 209; public on 14 Nov 2025
31 Dec 2025 report: 232; public on 17 Feb 2026
31 Mar 2026 report: 227; public on 15 May 2026
30 Jun 2026 report: 233; public on 14 Aug 2026
30 Sep 2026 report: 241; public on 16 Nov 2026
Federal obligations
Month from 1 Jul 2026: $73K published
Lobbying spend
Quarter from 1 Jan 2022: $40K published
Quarter from 1 Apr 2022: $40K published
Quarter from 1 Jul 2022: $40K published
Quarter from 1 Oct 2022: $40K published
Quarter from 1 Jan 2023: $40K published
Quarter from 1 Apr 2023: $40K published
Quarter from 1 Jul 2023: $40K published
Quarter from 1 Oct 2023: $40K published
Quarter from 1 Jan 2024: $40K published
Quarter from 1 Jul 2025: $20K published
Quarter from 1 Oct 2025: $10K published
Quarter from 1 Jan 2026: $20K published
Quarter from 1 Apr 2026: $70K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Made public in the last 90 days: it reported revenue of $55.4M for the quarter ended 30 Sep 2026, 4.3× the same quarter last year.
  • Quarterly revenue change: reported revenue of $44.7M for the quarter ended 30 Jun 2026, 3.6× the same quarter last year Public on 4 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $4.9M in the last 12 months (the 12 months before: -$4.1M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 10 published in the last 12 months, +25% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $371K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
28 Oct 2026Sarah GheuensChief Medical OfficerSellplanned in advance (10b5-1); after exercising options7,866$37.69$296KForm 4
23 Oct 2026Sarah GheuensChief Medical OfficerSellplanned in advance (10b5-1); after exercising options1,989$37.53$75KForm 4
6 Aug 2026Sarah GheuensChief Medical OfficerSellplanned in advance (10b5-1)30,000$30.48$914KForm 4
2 Jul 2026Sarah GheuensChief Medical OfficerSellplanned in advance (10b5-1); after exercising options4,007$37.56$151KForm 4
6 Apr 2026Tsveta MilanovaChief Commercial OfficerSellplanned in advance (10b5-1); after exercising options3,262$34.71$113KForm 4
6 Apr 2026Cecilia JonesChief Financial OfficerSellplanned in advance (10b5-1); after exercising options3,141$34.71$109KForm 4
6 Apr 2026James William BurnsChief Legal OfficerSellplanned in advance (10b5-1); after exercising options3,280$34.71$114KForm 4
6 Apr 2026Krishnan ViswanadhanChief Corp Dev & StrategySellplanned in advance (10b5-1); after exercising options2,959$34.71$103KForm 4

241 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 29 opened a position, 26 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.6.2M10.4%$207.1M-227K-3.5%
Farallon Capital Management, L.L.C.5.9M9.93%$197.5M+22K+0.4%
D. E. Shaw & Co., Inc.3.9M6.50%$129.3M+782K+25%
Morgan Stanley3.4M5.75%$114.3M+2.5M+257%
State Street Corp3.3M5.46%$108.5M-269K-7.6%
Vanguard Portfolio Management LLC2.9M4.77%$94.8M-48K-1.7%
Vanguard Capital Management LLC2.7M4.49%$89.4M+6,006+0.2%
Armistice Capital, LLC2.6M4.31%$85.7M+178K+7.4%
Nomura Asset Management International Inc.2.0M3.27%$65.1M-152K-7.2%
Assenagon Asset Management S.A.1.9M3.15%$62.7M+1.7M+807%

Company events

All 50 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
18 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
8 Jul 2025Director or officer change8-K
18 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
13 Feb 2025Director or officer change8-K
28 May 2024Signed a major agreement8-K
14 Jun 2023Director or officer changeSame filing: shareholder vote results8-K
25 May 2023Director or officer change8-K
19 Apr 2023Director or officer change8-K

Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
26 May 2026NewGridiron Public Affairs, LLCfor Agios PharmaceuticalsIssues related to patient access to innovative therapiesHealth issuesFiling
24 Nov 2025NewJeffrey J. Kimbell & Associates, Inc.for Agios Pharmaceuticals, Inc.issues related to prescription drugsHealth issuesFiling
12 Jun 2025NewAgios Pharmaceuticalsits own lobbyistsPharmacy, Medicare/Medicaid, Health IssuesPharmacy, Medicare/Medicaid, Health issuesFiling
31 Dec 2023EndedTiber Creek Groupfor Agios Pharmaceuticals Inc.Not statedFiling
8 Jan 2021NewTiber Creek Groupfor Agios Pharmaceuticals Inc.Issues related to the pharmaceutical industry.Health issuesFiling
30 Mar 2012EndedThe Petrizzo Group, Inc.for Agios Pharmaceuticals, Inc.Advocated for NIH Federal Funding related to radiation exposure; Advocated for NIH Federal Funding related to radiation exposure.Defense, Budget, Health issuesFiling
1 May 2009NewThe Petrizzo Group, Inc.for Agios Pharmaceuticals, Inc.Advance federal funding for research into cancer metabolism and the development of therapies that disrupt the growth and survival of cancer cells.Health issues, MEDFiling

The 5 newest of 156 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Feb 2026confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Agios Pharmaceuticals (AGIO): had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year, while it reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Short interest and volume: Short interest spike, became public on 28 Jan 2026
  • Financials: Quarterly revenue change, became public on 17 Feb 2026
2025-01-15: 5.3M2025-01-31: 5.0M2025-02-14: 4.6M2025-02-28: 3.9M2025-03-14: 3.4M2025-03-31: 3.5M2025-04-15: 3.5M2025-04-30: 3.9M2025-05-15: 4.2M2025-05-30: 4.3M2025-06-13: 4.3M2025-06-30: 3.8M2025-07-15: 4.2M2025-07-31: 4.1M2025-08-15: 4.8M2025-08-29: 4.8M2025-09-15: 4.7M2025-09-30: 5.2M2025-10-15: 5.0M2025-10-31: 4.6M2025-11-14: 4.3M2025-11-28: 5.5M2025-12-15: 6.1M2025-12-31: 7.1M2026-01-15: 7.4M
The 15 Jan 2026 report against the 24 reports before it. this reportearliernormal: 4.5M
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 28 Jan 2026

Agios Pharmaceuticals had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year.

This period
7.4M (the 15 Jan 2026 report)
Normal report (median of 24 earlier)
4.5M
Typical spread (median absolute deviation)
517K
How far from its usual level
+3.9
Same report last year
5.3M
History used
2,939 days
2025-01-15: 5.3M2025-01-31: 5.0M2025-02-14: 4.6M2025-02-28: 3.9M2025-03-14: 3.4M2025-03-31: 3.5M2025-04-15: 3.5M2025-04-30: 3.9M2025-05-15: 4.2M2025-05-30: 4.3M2025-06-13: 4.3M2025-06-30: 3.8M2025-07-15: 4.2M2025-07-31: 4.1M2025-08-15: 4.8M2025-08-29: 4.8M2025-09-15: 4.7M2025-09-30: 5.2M2025-10-15: 5.0M2025-10-31: 4.6M2025-11-14: 4.3M2025-11-28: 5.5M2025-12-15: 6.1M2025-12-31: 7.1M2026-01-15: 7.4M
the 15 Jan 2026 report24 earlier reportsnormal: 4.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 17 Feb 2026

Agios Pharmaceuticals reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year.

This period
$20.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$8.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+6.3
Same quarter last year
$10.7M
History used
5,023 days
2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M2025-12-31: $20.0M
the quarter ended 31 Dec 20258 earlier quartersnormal: $8.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

5 Aug 2025confirmed

Confirmed across sources Filings + Financials and Lobbying

Agios Pharmaceuticals (AGIO): lobbying on a new issue, while it reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year. Two unrelated kinds of activity within 14 days.

  • Lobbying: Lobbying on a new issue, became public on 22 Jul 2025
  • Financials: Quarterly revenue change, became public on 5 Aug 2025
2023-06-30: $6.7M2023-09-30: $7.4M2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M
The quarter ended 30 Jun 2025 against the 8 quarters before it. this quarterearliernormal: $8.4M
See the evidence (2 changes)

Lobbying: Lobbying on a new issue became public on 22 Jul 2025

Agios Pharmaceuticals lobbying on a new issue.

New
['MMM', 'PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
4821615

Financials: Quarterly revenue change became public on 5 Aug 2025

Agios Pharmaceuticals reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.

This period
$12.5M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$8.4M
Typical spread (median absolute deviation)
$782K
How far from its usual level
+3.5
Same quarter last year
$8.6M
History used
4,839 days
2023-06-30: $6.7M2023-09-30: $7.4M2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M
the quarter ended 30 Jun 20258 earlier quartersnormal: $8.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

5 Mar 2019confirmed

Confirmed across sources Filings + Financials and Short interest and volume

Agios Pharmaceuticals (AGIO): reported revenue of $30.0M for the quarter ended 31 Dec 2018, 3.1× the same quarter last year, while it had 7.8M shares sold short in the 28 Feb 2019 report, 1.5× the same report last year. Two unrelated kinds of activity within 21 days.

  • Financials: Quarterly revenue change, became public on 19 Feb 2019
  • Short interest and volume: Short interest spike, became public on 28 Feb 2019
  • Short interest and volume: Short interest spike, became public on 12 Mar 2019
2016-12-31: $22.6M2017-03-31: $10.5M2017-06-30: $11.3M2017-09-30: $11.4M2017-12-31: $9.8M2018-03-31: $8.8M2018-06-30: $40.4M2018-09-30: $15.2M2018-12-31: $30.0M
The quarter ended 31 Dec 2018 against the 8 quarters before it. this quarterearliernormal: $11.4M
See the evidence (3 changes)

Financials: Quarterly revenue change became public on 19 Feb 2019

Agios Pharmaceuticals reported revenue of $30.0M for the quarter ended 31 Dec 2018, 3.1× the same quarter last year.

This period
$30.0M (the quarter ended 31 Dec 2018)
Normal quarter (median of 8 earlier)
$11.4M
Typical spread (median absolute deviation)
$2.1M
How far from its usual level
+6.1
Same quarter last year
$9.8M
History used
2,466 days
2016-12-31: $22.6M2017-03-31: $10.5M2017-06-30: $11.3M2017-09-30: $11.4M2017-12-31: $9.8M2018-03-31: $8.8M2018-06-30: $40.4M2018-09-30: $15.2M2018-12-31: $30.0M
the quarter ended 31 Dec 20188 earlier quartersnormal: $11.4M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 28 Feb 2019

Agios Pharmaceuticals had 7.3M shares sold short in the 15 Feb 2019 report, 1.3× the same report last year.

This period
7.3M (the 15 Feb 2019 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
360K
How far from its usual level
+3.6
Same report last year
5.8M
History used
413 days
2018-02-15: 5.8M2018-02-28: 5.3M2018-03-15: 5.3M2018-03-29: 5.6M2018-04-13: 5.5M2018-04-30: 5.1M2018-05-15: 5.0M2018-05-31: 4.8M2018-06-15: 5.1M2018-06-29: 4.9M2018-07-13: 4.7M2018-07-31: 5.0M2018-08-15: 5.1M2018-08-31: 5.1M2018-09-14: 5.2M2018-09-28: 5.7M2018-10-15: 5.6M2018-10-31: 6.4M2018-11-15: 6.9M2018-11-30: 6.5M2018-12-14: 6.5M2018-12-31: 7.0M2019-01-15: 7.2M2019-01-31: 7.2M2019-02-15: 7.3M
the 15 Feb 2019 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Mar 2019

Agios Pharmaceuticals had 7.8M shares sold short in the 28 Feb 2019 report, 1.5× the same report last year.

This period
7.8M (the 28 Feb 2019 report)
Normal report (median of 24 earlier)
5.4M
Typical spread (median absolute deviation)
360K
How far from its usual level
+4.5
Same report last year
5.3M
History used
426 days
2018-02-28: 5.3M2018-03-15: 5.3M2018-03-29: 5.6M2018-04-13: 5.5M2018-04-30: 5.1M2018-05-15: 5.0M2018-05-31: 4.8M2018-06-15: 5.1M2018-06-29: 4.9M2018-07-13: 4.7M2018-07-31: 5.0M2018-08-15: 5.1M2018-08-31: 5.1M2018-09-14: 5.2M2018-09-28: 5.7M2018-10-15: 5.6M2018-10-31: 6.4M2018-11-15: 6.9M2018-11-30: 6.5M2018-12-14: 6.5M2018-12-31: 7.0M2019-01-15: 7.2M2019-01-31: 7.2M2019-02-15: 7.3M2019-02-28: 7.8M
the 28 Feb 2019 report24 earlier reportsnormal: 5.4M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 10 Nov 2026Financials change

    reported revenue of $55.4M for the quarter ended 30 Sep 2026, 4.3× the same quarter last year.

    Same quarter last year: $12.9M; its normal quarter is $12.7M.

    See the evidence
    This period
    $55.4M (the quarter ended 30 Sep 2026)
    Normal quarter (median of 8 earlier)
    $12.7M
    Typical spread (median absolute deviation)
    $3.8M
    How far from its usual level
    +7.5
    Same quarter last year
    $12.9M
    History used
    5,296 days
    2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M2025-12-31: $20.0M2026-03-31: $20.7M2026-06-30: $44.7M2026-09-30: $55.4M
    the quarter ended 30 Sep 20268 earlier quartersnormal: $12.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 4 Aug 2026Financials change

    reported revenue of $44.7M for the quarter ended 30 Jun 2026, 3.6× the same quarter last year.

    Same quarter last year: $12.5M; its normal quarter is $11.6M.

    See the evidence
    This period
    $44.7M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $11.6M
    Typical spread (median absolute deviation)
    $2.7M
    How far from its usual level
    +8.1
    Same quarter last year
    $12.5M
    History used
    5,204 days
    2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M2025-12-31: $20.0M2026-03-31: $20.7M2026-06-30: $44.7M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $11.6M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  3. 18 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 18 Jun 2026Filings record

    Director or officer change

  5. 26 May 2026Lobbying record

    AGIOS PHARMACEUTICALS: new lobbying registration (GRIDIRON PUBLIC AFFAIRS, LLC)

  6. 30 Apr 2026Financials change

    reported revenue of $20.7M for the quarter ended 31 Mar 2026, 2.4× the same quarter last year.

    Same quarter last year: $8.7M; its normal quarter is $9.8M.

    See the evidence
    This period
    $20.7M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $9.8M
    Typical spread (median absolute deviation)
    $1.4M
    How far from its usual level
    +5.1
    Same quarter last year
    $8.7M
    History used
    3,652 days
    2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M2025-12-31: $20.0M2026-03-31: $20.7M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $9.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 17 Feb 2026several at once

    had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year, while it reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 28 Jan 2026

    Agios Pharmaceuticals had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year.

    This period
    7.4M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.5M
    Typical spread (median absolute deviation)
    517K
    How far from its usual level
    +3.9
    Same report last year
    5.3M
    History used
    2,939 days
    2025-01-15: 5.3M2025-01-31: 5.0M2025-02-14: 4.6M2025-02-28: 3.9M2025-03-14: 3.4M2025-03-31: 3.5M2025-04-15: 3.5M2025-04-30: 3.9M2025-05-15: 4.2M2025-05-30: 4.3M2025-06-13: 4.3M2025-06-30: 3.8M2025-07-15: 4.2M2025-07-31: 4.1M2025-08-15: 4.8M2025-08-29: 4.8M2025-09-15: 4.7M2025-09-30: 5.2M2025-10-15: 5.0M2025-10-31: 4.6M2025-11-14: 4.3M2025-11-28: 5.5M2025-12-15: 6.1M2025-12-31: 7.1M2026-01-15: 7.4M
    the 15 Jan 2026 report24 earlier reportsnormal: 4.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 17 Feb 2026

    Agios Pharmaceuticals reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year.

    This period
    $20.0M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $8.8M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    +6.3
    Same quarter last year
    $10.7M
    History used
    5,023 days
    2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M2025-12-31: $20.0M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $8.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  8. 17 Feb 2026Financials change

    reported revenue of $20.0M for the quarter ended 31 Dec 2025, 1.9× the same quarter last year.

    Same quarter last year: $10.7M; its normal quarter is $8.8M.

    See the evidence
    This period
    $20.0M (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    $8.8M
    Typical spread (median absolute deviation)
    $1.2M
    How far from its usual level
    +6.3
    Same quarter last year
    $10.7M
    History used
    5,023 days
    2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M2025-12-31: $20.0M
    the quarter ended 31 Dec 20258 earlier quartersnormal: $8.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  9. 28 Jan 2026Short interest and volume change

    had 7.4M shares sold short in the 15 Jan 2026 report, 1.4× the same report last year.

    Same report last year: 5.3M; its normal report is 4.5M.

    See the evidence
    This period
    7.4M (the 15 Jan 2026 report)
    Normal report (median of 24 earlier)
    4.5M
    Typical spread (median absolute deviation)
    517K
    How far from its usual level
    +3.9
    Same report last year
    5.3M
    History used
    2,939 days
    2025-01-15: 5.3M2025-01-31: 5.0M2025-02-14: 4.6M2025-02-28: 3.9M2025-03-14: 3.4M2025-03-31: 3.5M2025-04-15: 3.5M2025-04-30: 3.9M2025-05-15: 4.2M2025-05-30: 4.3M2025-06-13: 4.3M2025-06-30: 3.8M2025-07-15: 4.2M2025-07-31: 4.1M2025-08-15: 4.8M2025-08-29: 4.8M2025-09-15: 4.7M2025-09-30: 5.2M2025-10-15: 5.0M2025-10-31: 4.6M2025-11-14: 4.3M2025-11-28: 5.5M2025-12-15: 6.1M2025-12-31: 7.1M2026-01-15: 7.4M
    the 15 Jan 2026 report24 earlier reportsnormal: 4.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  10. 9 Jan 2026Lobbying record

    AGIOS PHARMACEUTICALS, INC.: new lobbying registration (JEFFREY J. KIMBELL & ASSOCIATES, INC.) (dated 24 Nov 2025)

  11. 4 Nov 2025Financials change

    reported revenue of $12.9M for the quarter ended 30 Sep 2025, 1.4× the same quarter last year.

    Same quarter last year: $9.0M; its normal quarter is $8.7M.

    See the evidence
    This period
    $12.9M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $8.7M
    Typical spread (median absolute deviation)
    $876K
    How far from its usual level
    +3.2
    Same quarter last year
    $9.0M
    History used
    4,931 days
    2023-09-30: $7.4M2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M2025-09-30: $12.9M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $8.7M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  12. 5 Aug 2025several at once

    lobbying on a new issue, while it reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year. Two unrelated kinds of activity within 14 days.

    See the evidence (2 changes)

    Lobbying: Lobbying on a new issue became public on 22 Jul 2025

    Agios Pharmaceuticals lobbying on a new issue.

    New
    ['MMM', 'PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4821615

    Financials: Quarterly revenue change became public on 5 Aug 2025

    Agios Pharmaceuticals reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.

    This period
    $12.5M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $8.4M
    Typical spread (median absolute deviation)
    $782K
    How far from its usual level
    +3.5
    Same quarter last year
    $8.6M
    History used
    4,839 days
    2023-06-30: $6.7M2023-09-30: $7.4M2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $8.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  13. 5 Aug 2025Financials change

    reported revenue of $12.5M for the quarter ended 30 Jun 2025, 1.4× the same quarter last year.

    Same quarter last year: $8.6M; its normal quarter is $8.4M.

    See the evidence
    This period
    $12.5M (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    $8.4M
    Typical spread (median absolute deviation)
    $782K
    How far from its usual level
    +3.5
    Same quarter last year
    $8.6M
    History used
    4,839 days
    2023-06-30: $6.7M2023-09-30: $7.4M2023-12-31: $7.1M2024-03-31: $8.2M2024-06-30: $8.6M2024-09-30: $9.0M2024-12-31: $10.7M2025-03-31: $8.7M2025-06-30: $12.5M
    the quarter ended 30 Jun 20258 earlier quartersnormal: $8.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  14. 22 Jul 2025Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['MMM', 'PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4821615
  15. 8 Jul 2025Filings record

    Director or officer change

  16. 18 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 18 Jun 2025Filings record

    Director or officer change

  18. 12 Jun 2025Lobbying record

    AGIOS PHARMACEUTICALS: new lobbying registration (in-house)

  19. 13 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 13 Feb 2025Filings record

    Director or officer change

  21. 25 Jan 2024Short interest and volume change

    had 8.0M shares sold short in the 12 Jan 2024 report, 1.2× the same report last year.

    Same report last year: 6.7M; its normal report is 5.9M.

    See the evidence
    This period
    8.0M (the 12 Jan 2024 report)
    Normal report (median of 24 earlier)
    5.9M
    Typical spread (median absolute deviation)
    143K
    How far from its usual level
    +3.6
    Same report last year
    6.7M
    History used
    2,205 days
    2023-01-13: 6.7M2023-01-31: 5.8M2023-02-15: 5.8M2023-02-28: 5.9M2023-03-15: 5.9M2023-03-31: 5.8M2023-04-14: 5.4M2023-04-28: 5.7M2023-05-15: 5.8M2023-05-31: 5.7M2023-06-15: 5.8M2023-06-30: 5.9M2023-07-14: 6.2M2023-07-31: 6.1M2023-08-15: 6.0M2023-08-31: 5.9M2023-09-15: 6.0M2023-09-29: 5.8M2023-10-13: 5.5M2023-10-31: 5.7M2023-11-15: 6.0M2023-11-30: 6.4M2023-12-15: 6.9M2023-12-29: 7.1M2024-01-12: 8.0M
    the 12 Jan 2024 report24 earlier reportsnormal: 5.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 16 Jan 2024Lobbying record

    AGIOS PHARMACEUTICALS INC.: lobbying engagement terminated (TIBER CREEK GROUP) (dated 31 Dec 2023)

  23. 14 Jun 2023Filings record

    Director or officer change

  24. 25 May 2023Filings record

    Director or officer change

  25. 19 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  26. 19 Apr 2023Filings record

    Director or officer change

  27. 16 Dec 2022Filings record

    Director or officer change

  28. 6 Dec 2022Filings record

    Director or officer change

  29. 7 Oct 2022Filings record

    Director or officer change

  30. 19 Sep 2022Filings record

    Director or officer change

  31. 7 Sep 2022Filings record

    Director or officer change

  32. 15 Aug 2022Filings record

    Director or officer change

  33. 12 Jul 2022Filings record

    Director or officer change

  34. 26 May 2022Filings record

    Director or officer change

  35. 18 May 2022Filings record

    Director or officer change

  36. 26 Apr 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 26 Apr 2022Filings record

    Director or officer change

  38. 25 Nov 2021Short interest and volume change

    had 7.6M shares sold short in the 15 Nov 2021 report, 1.4× the same report last year.

    Same report last year: 5.6M; its normal report is 5.5M.

    See the evidence
    This period
    7.6M (the 15 Nov 2021 report)
    Normal report (median of 24 earlier)
    5.5M
    Typical spread (median absolute deviation)
    310K
    How far from its usual level
    +3.7
    Same report last year
    5.6M
    History used
    1,417 days
    2020-11-13: 5.6M2020-11-30: 5.0M2020-12-15: 5.4M2020-12-31: 5.8M2021-01-15: 5.5M2021-01-29: 5.5M2021-02-12: 5.7M2021-02-26: 5.8M2021-03-15: 6.3M2021-03-31: 5.3M2021-04-15: 5.5M2021-04-30: 5.4M2021-05-14: 5.1M2021-05-28: 4.7M2021-06-15: 4.5M2021-06-30: 4.6M2021-07-15: 5.0M2021-07-30: 4.8M2021-08-13: 5.6M2021-08-31: 5.6M2021-09-15: 5.7M2021-09-30: 6.2M2021-10-15: 6.7M2021-10-29: 7.0M2021-11-15: 7.6M
    the 15 Nov 2021 report24 earlier reportsnormal: 5.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  39. 4 Aug 2021Filings record

    Director or officer change

  40. 29 Jul 2021Filings record

    Director or officer change

Showing the newest 40 of 80 entries; narrow the window or the kind of data to see older ones.

Not listed: 398 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001439222
Ticker
AGIO
Domain
agios.com
Employer name
AGIOS PHARMACEUTICALS, INC. (1 unverified)
Hq location
MA|CAMBRIDGE|02139 (1 unverified)
Lobbying client
agios pharmaceuticals
Name
Agios France SARL, Agios Germany GmbH, Agios International Sarl (GmbH), Agios Italy S.R.L and 4 more
Uei
H7M5XL4EHLQ4, KKWAB4MN58M3, ME2BQHBUZJC3
Wikidata
Q16824426
Wikipedia
Agios Pharmaceuticals
  • DOL H-1B labor condition applications and PERM certifications321 data points1 Oct 2019 to 21 Sep 2026
  • Federal lobbying disclosures (LDA)7 records, 86 data points1 May 2009 to 30 Sep 2026
  • SEC Form 13F institutional holdings477 data points30 Sep 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)195 records11 Jan 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1023 data points31 Dec 2010 to 30 Oct 2026
  • SEC Form 4 insider transactions246 records, 736 data points5 Jan 2016 to 28 Oct 2026
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards9 data points7 Feb 2011 to 14 Jul 2026
  • Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026